Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22835971 | 1.00 | DDB1 (0.55) | DDB1CRBNGPR119PDK2ALDH1A1 | |
| SCHEMBL30768477 | 1.00 | DDB1 (0.55) | DDB1CRBNGPR119PDK2ALDH1A1 | |
| SCHEMBL23541316 | 0.94 | DDB1 (0.51) | DDB1CRBNGPR119 | |
| SCHEMBL26102384 | 0.93 | DDB1 (0.49) | DDB1CRBNGPR119 | |
| SCHEMBL26101785 | 0.93 | DDB1 (0.49) | DDB1CRBNGPR119 | |
| SCHEMBL26101026 | 0.93 | CRBN (0.54) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL24480677 | 0.93 | DDB1 (0.48) | DDB1CRBNGPR119 | |
| SCHEMBL29579169 | 0.93 | DDB1 (0.48) | DDB1CRBNGPR119 | |
| SCHEMBL26098702 | 0.93 | DDB1 (0.48) | DDB1CRBNGPR119 | |
| SCHEMBL30289268 | 0.92 | DDB1 (0.49) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | DDB1 2204/4885CRBN 488/4885GPR119 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.